Latest / Success Story with Scott Clary / Lessons - Creating and Scaling a Ketamine Company | Jose Muñoz Aycart - Co-Founder of Wondermed
Transcript
- 0:00Want to take a look at how you build a ketamine ketamine company
- 0:05Because how did you how did you going into this
- 0:08Even start to think about the commercial structure how to build it out how to scale it
- 0:14I mean if you are blue ocean then you don't have a lot of examples to look to right?
- 0:18So you're going in day one you know like listen
- 0:20I am entrepreneurial. I have a mind for business. I'm going in but
- 0:26There's a million different ways to revenue. There's a million different
- 0:29Legal items that I have to you know deal with so what what is it day one going to this is as the new CEO
- 0:37Um to to that point. I think you've been calling me a CEO. I appreciate that a lot
- 0:41I'll go founder as well. I'm a co-founder and managing director Ryan is the co-founder and CEO of the company. Oh, okay
- 0:46Still fantastic duo. That's how that's how we call each other
- 0:49um and
- 0:51Day one is a puzzle without the pieces
- 0:54If you've ever built a puzzle you start going to the boundaries the edges of the puzzle
- 0:58And you start kind of creating what the overarching structure is going to be of the building of of the of the build
- 1:04In this case in the company we started looking at all the different boundaries from legal boundaries to
- 1:09business model boundaries of margins
- 1:11What the legality in each single state was because he's very different what the federal guidelines were
- 1:18And we started putting the pieces together. It actually took us
- 1:20Two years to launch the company that you see today and that people are able to benefit from and a lot of those things were to your point a lot of
- 1:29Thought provoking exercises with experts in the legal field things that have been happening on the telemedicine space
- 1:35Things that had been happening in the off-label prescription space. We learned from past mistakes
- 1:39And most importantly from present mistakes a lot of it was a proper build of a structure that
- 1:45Took a lot of resources and a lot of time
- 1:47And wouldn't have been possible without the team that we were able to assemble the experts that came in and help the company
- 1:54Get to where it is today and how did you you raised 5.6 in a seed
- 1:58raised 5.6 million dollars in a seed round. How do you find investors for this?
- 2:03You know, there's a very common trade out of a lot of investors that have come into the company and that is their own
- 2:09Self-actualization their own self-improvement through the medicine
- 2:13So a lot of people have come to these because they have been able to have their opportunity
- 2:16To experience it and experience the positive impact of it and realize that the one this to be something that more people can benefit from
- 2:24We're also getting a lot of investors
- 2:26Interested in early-stage industries or markets. I think psychedelic is a market more than an industry and
- 2:34You know with that risk with that innovation comes the reward and I think that some investors that are
- 2:40Business savvy and they're interested in looking at
- 2:43I mean things from consumer branding perspective to actual technology
- 2:48The way we see it as I mentioned before
- 2:50Keremin or psychedelic substances are a technology that we need to maneuver that we need to master that we need to improve
- 2:56And at the same time it is a service because it is an experience and it is a product because it is a substance
- 3:01And so all of these things put together
- 3:04Are a very unique type of business model that when you add on top of that the fact that every single
- 3:10patient interaction is unique and different you have really even a
- 3:16marketing exceptional opportunity to understand how to
- 3:20talk and
- 3:22Provide people with the necessary knowledge for them to do it was it was it hard to raise the money
- 3:27It was difficult, but I think that the support that we've been seeing from our investors has been
- 3:32And once you get this once you get them on board
- 3:35How did you find the the 5.6?
- 3:38It took us some time we've actually didn't do it in a in a full block
- 3:41We wanted to do it in a you know kind of pragmatic way of understanding how the business
- 3:46Went through a building a stage and I started pivoting to a growth stage and within the same round investors have been coming in different points and
- 3:58Positive impact. I think that what I started talking at the beginning of how tough it was to go to some investors
- 4:03The psychedelic industry and market has been
- 4:06Time after time bringing experts and investors into the space understanding why we're doing this for what reasons and
- 4:13That made it pretty easy to
- 4:16To make people feel that they had the possibility of making a change and they weren't the investors
- 4:20They didn't have concerns of regulatory uncertainty. Of course they did
- 4:23Yeah, the investors that we have in the company are some of the most brilliant people I've ever met in my life and the conversations that we had
- 4:29This is not a happy happy
- 4:31Situation. This is not a super easy type of market the building in itself from a structural standpoint is incredibly complicated
- 4:38the contextual risk of illegal and regulatory
- 4:42Components is also very risky, but
- 4:46It is a matter of looking at it understanding what the changes would look like
- 4:50How we will adapt and if you have a team that is able to adapt to any form of change
- 4:54You will have a successful company and I think that investors as I mentioned before provided that type of
- 5:00Of inside just from conversation those that invested and those that did not invest
- 5:04The conversations that I've had with investors in this company has been quite quite unique